Anavex Life Sciences Corp (AVXL)

[nidan7500]

Find it hard to understand how abig regulartory body (in this case FDA) has been so consistently wrong for sooo MANNNY years and still keep it's doors open. WOW...NEVER MIND...

The U.S. Food and Drug Administration will expedite its review of Eisai Co Ltd's (4523.T) and Biogen Inc's (BIIB.O) experimental Alzheimer's drug lecanemab, with a decision due by Jan 6, 2023, the companies said on Tuesday.

Lecanemab, like the partners' previous drug Aduhelm, is an antibody designed to remove sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimer’s, a disease that leads to memory loss and the inability to care for oneself.

HUH??REALLY??